VIEWS: 62 PAGES: 4 CATEGORY: Resumes POSTED ON: 2/8/2013
Paul Lambotte has over 30 years with a consistent record of planning highly successful Clinical Diagnostic product strategies and developing innovative products and platforms with established and start-up companies.
Paul Lambotte, PhD Tel: 858-353-0361 San Diego, CA 92122 Email: Plambotte@me.com PROFILE SUMMARY EXECUTIVE • STRATEGIC PLANNING • PRODUCT DEVELOPMENT Over 30 years with a consistent record of planning highly successful Clinical Diagnostic product strategies and developing innovative products and platforms with established and start-up companies. Successful leader and facilitator of development teams, matrix organizations and collaborative projects between companies. Ability to identify industry trends, to use broad scientific background and deep understanding of the in vitro diagnostic market to create innovative platform and product strategies, opening access to new markets, to long-term contracts with new customers, generating multimillion dollars in new revenues. Experienced as an entrepreneur in successfully planning and executing the strategy of a medical device company. SUMMARY OF QUALIFICATIONS Leverage scientific background, business acumen and understanding of the IVD market needs to craft innovative platform and product strategies for large and small companies Expert in scouting for new In Vitro Diagnostic technologies, for new fields of applications and for innovative companies Abreast of the latest progress in rapid nucleic acid diagnostic and immuno-diagnostic technologies in a changing environment Experienced, enthusiastic and motivated leader of R&D organizations, multidisciplinary projects and joint collaborations between companies Successful entrepreneurial record of planning and executing the strategy of a start-up company Consulting practice in the areas of In Vitro Diagnostic, Point of Care Diagnostic, clinical diagnostic product development and instrumented platforms EXPERIENCE AXXIN Pty Ltd – Compact, cutting edge instrumentation for Point-of-Care Testing Apr 2009-Dec 2012 Chief Scientific Officer Crafted company strategy by selecting innovative technologies and product lines. Identified key clients and initiated business negotiations that lead to multimillion-dollar contracts with major players in the field. Supported the successful development of cutting edge instruments from concept to market. 1 Used keen understanding of the Clinical Diagnostic Market needs and trends, and of the capabilities and skills of the start-up team to select the most promising instrument lines to develop. Initiated the development of a cutting edge rapid nucleic acid molecular amplification platform for the point of care. Highly successful introduction of the molecular amplification platform on the marketplace is being followed by other instruments based on the same technology Identified potential clients from wide network of relationships. Initiated discussions and contract building negotiations, resulting in highly profitable business deals with several key players in the In Vitro Diagnostic market both in human and non-human fields Wrote successful grant applications, obtaining $1.5 M dollar funding to support the development of an innovative instrumented platform for rapid and accurate detection of drugs of abuse at the point of collection Participated in crafting an exit strategy for the company that will provide good return to the shareholders QUIDEL CORPORATION – Rapid Diagnostic Tests for the Point-of-Care Jan 2000- Mar 2009 Director, Strategic Technology Initiatives (2005- 2009) Developed a strategy to increase market leadership and penetration by introducing a new rapid molecular diagnostic technology platform and expanding the strength of a proprietary immunoassay platform. The company has successfully adopted the strategy in 2009 and is still executing it. Performed a comprehensive study of the IVD market, players, companies, users and of the requirements of the changing healthcare industry Identified the elements required to develop an innovative rapid diagnostic strategy for the point of care, including both improved immunoassay and novel nucleic acid rapid amplification technologies Identified, evaluated and recommended technologies and companies required to bring such new rapid in vitro diagnostic platforms to market Conducted due diligence of potential acquisitions or collaborations, participated in the financial modeling and presented recommendations to the Board of Directors Proposed a comprehensive strategic plan to transition from the current to the new technology platforms, including financial and market analyses. The plan has been adopted and is being executed with significant expansion of the company’s market footprint and financial revenues Director, Joint Project Development (2003-2005) Built business relationships with major players in the Over-the-Counter (OTC) diagnostic product field with the purpose of evaluating opportunities to bring rapid diagnostic tests to the consumer market. Studied the consumer market, initiated contact and exploratory conversations with major OTC companies. With them, designed and conducted users’ requirement studies, focus groups, market studies and financial analyses. 2 VP of R&D (2000-2003) Restructured R&D. Led and completed major product and process development projects including two products that became today’s company flagship products. Led improvement projects that generated multi-million dollars in savings and allowed keeping manufacturing in the USA Reorganized and energized the R&D and Process Development groups to develop highly successful new products while improving efficiencies, reducing manufacturing costs, resulting in multimillion dollar cost reduction and eliminating backlogs Recommended and led the development of a rapid diagnostic test for the differential diagnosis of Influenza A and B. The test was first on the market and became the company’s flagship product thanks to its exceptional quality and reliability Led a major project for automating the manufacturing of rapid lateral flow tests, resulting in the launch of a key product with a significant increase in performance, quality, productivity and gross margin. Initiated the conversion of Quidel’s product line to the new manufacturing process, eliminating the need for moving manufacturing to countries with lower manufacturing costs. HYBRITECH/BECKMAN-COULTER CORPORATION. – Diagnostic product development 1995-1999 Director, Process Development Led the improvement of the production process of Hybritech’s lead product (PSA test), resulting in a better and more consistent product with higher gross margin. Led the relocation and integration of the point of care products manufacturing facility following the acquisition of Hybritech by Beckman-Coulter HYBRITECH / ELI LILLY CORPORATION 1988-1995 Product Development Manager, R&D Responsible for leading several new rapid diagnostic product development projects and managed a development team located out of state, in a joint development project with a top player in the clinical diagnostic industry HYBRITECH-BELGIUM 1984-1988 Senior Scientist, Group Leader Actively participated in setting up the R&D facility; led multiple product development projects on a innovative rapid diagnostic platform, leading to my transfer to the San Diego headquarters to lead development projects EDUCATION BS, MS in Chemistry, University of Mons, Belgium Ph.D. in Biochemistry, University of Mons, Belgium Post Doc: Ludwig Institute for Cancer Research, Brussels, Belgium Teaching Credentials 3 CERTIFICATIONS Multiple courses in diverse areas of business management and in vitro diagnostic technologies including Global Business Management, Auditing, Finance, Quality, Teamwork, Process Optimization, Design of Experiments, Nucleic acid Methods, Infectious Diseases, trends in diagnostic testing etc. PUBLICATIONS AND PATENTS AVAILABLE UPON REQUEST 4
"VP Strategic Business Development in San Diego CA Resume Paul Lambotte"